Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Antitumor activity of intraperitoneal (IP) paclitaxel to mucinous appendiceal adenocarcinoma in orthotopic patient-derived xenograft model.
Authors
Ichiaki Ito
University of Texas MD Anderson Cancer Center, Houston, TX;
Ichiaki Ito , Abdelrahman M.G. Yousef , Princess A Dickson , Keith F. Fournier , Natalie Wall Fowlkes , John Paul Y.C. Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 151)
DOI
10.1200/JCO.2023.41.4_suppl.151
Abstract #
151
Poster Bd #
H10
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma.
First Author: John Paul Y.C. Shen
Poster
2016 ASCO Annual Meeting
Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma.
First Author: Maria Ignez Freitas Melro Braghiroli
Poster
2016 Gastrointestinal Cancers Symposium
Genomic profiling and efficacy of anti-EGFR therapy in appendiceal adenocarcinoma.
First Author: Maria Ignez Freitas Melro Braghiroli
Poster
2015 ASCO Annual Meeting
Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.
First Author: Esther CW Breij